vrc-malmab0100-00-ab
mAbexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2020 (NCT04206332)
Timeline
Indications
Mechanism of action
- Plasmodium falciparumImmunity, passive
Plasmodium falciparum immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04329104 | Phase 2 | Mar 31, 2021 | Harvard University, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), University of Washington |
| NCT04206332 | Phase 1 | Jan 1, 2020 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 2 | 2020 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2021 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1